Drug intelligence / Profile preview

TLTaxel

Development stage: Preclinical
Lead developer: InnoMedica
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

TLTaxel is a liposomal formulation of docetaxel being developed by InnoMedica for the treatment of cancer. It utilizes a proprietary lipid nanoparticle (LNP) technology platform to encapsulate docetaxel, a taxane-based cytotoxic agent that stabilizes microtubules and inhibits cell division. This liposomal delivery system is designed to improve the pharmacokinetic profile and tumor-specific accumulation of docetaxel while reducing the systemic toxicities and hypersensitivity reactions associated with conventional docetaxel formulations, which typically require the use of the solvent Tween 80. TLTaxel is currently in the preclinical stage of development.

Other names: liposomal docetaxel

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on TLTaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLTaxel.

Explore the full profile